|
WO2021023724A1
|
|
System simulating a decisional process in a mammal brain about motions of a visually observed body
|
|
WO2021016715A1
|
|
Systems and methods for movement modulation of a body part of a subject
|
|
WO2020257922A1
|
|
Novel tumor-specific antigens for ovarian cancer and uses thereof
|
|
WO2020223821A1
|
|
Miha peptide combinations and uses thereof
|
|
CA3060963A1
|
|
Limb sparing in mammals using patient-specific endoprostheses and cutting guides
|
|
SG11202100528YA
|
|
Proteogenomic-based method for identifying tumor-specific antigens
|
|
WO2019232640A1
|
|
Method for the identification and design of rna interference agents
|
|
CN112135618A
|
|
Amplification of NK and DC cells mediating immune response in vivo
|
|
KR20200092982A
|
|
Medical device and method for managing ocular axial contraction growth in the context of refractive abnormality progression
|
|
KR20200084873A
|
|
Use in the proliferation of compounds and stem cells and/or progenitor cells
|
|
WO2019075556A1
|
|
Systems and methods for the assessment of g-protein activation
|
|
WO2019060994A1
|
|
Compounds for use in the treatment or prevention of lowe syndrome or dent disease, and methods therefor
|
|
AU2018225825A1
|
|
Novel minor histocompatibility antigens and uses thereof
|
|
CA2995617A1
|
|
Heterocyclic mitochondrial activity inhibitors and uses thereof
|
|
WO2017205977A1
|
|
Selection of human hematopoetic stem cells using epcr
|
|
AU2016353547A1
|
|
Cyclic peptides targeting α4β7 integrin
|
|
WO2017066863A1
|
|
Heterocyclic compounds as inhibitors of platelet aggregation
|
|
CA2937896A1
|
|
Use of mubritinib for the treatment of poor prognosis acute myeloid leukemia
|
|
US2018127831A1
|
|
Prognostic markers of acute myeloid leukemia survival
|
|
CA2963579A1
|
|
Biosensor based on g-beta-gamma-interacting proteins to monitor g-protein activation
|
